JESSICA FOGELTANZ: Open Payments
NPI 1477942647 · CAMARILLO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,047 in 43 payments from 12 companies in 2025. Trend: 2023 $1,012 · 2024 $523 · 2025 $1,047
Food & beverage: $1,047
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $451 |
| ABBVIE INC. | 6 | $121 |
| Merck Sharp & Dohme LLC | 3 | $90 |
| AstraZeneca Pharmaceuticals LP | 3 | $76 |
| Astellas Pharma US Inc | 2 | $58 |
| Amgen Inc. | 2 | $56 |
| Lilly USA, LLC | 2 | $52 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Exact Sciences Corporation | 1 | $30 |
| PFIZER INC. | 1 | $27 |
Products named: Ozempic, Rybelsus, CAPVAXIVE, Wegovy, Veozah, EVENITY, QULIPTA, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
